罗氟司特效果怎么样？

The EU approved the marketing of roflumilast (Daxas) in July 2010, which is mainly used for the treatment of chronic obstructive pulmonary disease (COPD). Roflumilast (Daxas) is a selective phosphodiesterase 4 (PDE4) inhibitor. Roflumilast (Daxas) is the first new class of chronic obstructive pulmonary disease (COPD) treatment drug approved by the EU in more than a decade. What's the effect like?

Four phase III clinical studies laid the foundation for the approval of roflumilast (Daxas). More than 3,000 patients with chronic obstructive pulmonary disease (COPD) were included in two pivotal placebo-controlled clinical studies. Studies have shown that roflumilast (Daxas) can significantly improve patients with moderate to severe exacerbations and prediastolic FEV1, regardless of whether it is combined with a long-acting β2 agonist. The study also demonstrated that roflumilast (Daxas) significantly improved patients' lung function compared with placebo. The therapeutic effect of Roflumilast (Daxas) is remarkable, but patients are not allowed to use this drug without authorization. Treatment with Roflumilast (Daxas) will also produce some adverse reactions.

Roflumilast adverse reactions

The most common adverse reactions of Roflumilast (Daxas): diarrhea, weight loss, nausea, headache, back pain, influenza, insomnia, dizziness, decreased appetite, etc. Once patients discover serious or intolerable side effects during treatment with roflumilast, they must seek medical help in time, and patients should not blindly use this drug for treatment.

Precautions for Roflumilast

Treatment with roflumilast (Daxas) may cause weight loss, so patients should check their weight frequently while receiving the drug. If unexplained or clinically significant weight loss occurs, discontinuation of roflumilast (Daxas) should be considered.

When using roflumilast (Daxas), attention should be paid to drug interactions. It is not recommended to use it with strong cytochrome P450 enzyme inducers (such as rifampicin, phenobarbital, carbamazepine, phenytoin).

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended hot articles: